CURRENT PERSPECTIVE ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE: FROM RISK FACTORS TO MULTIMORBIDITY
https://doi.org/10.52485/19986173_2026_2_153
Abstract
Chronic obstructive pulmonary disease (COPD) is a complex disorder involving multiple contributing factors. COPD risk factors encompass various aspects of modern life. Special attention is given to environmental exposure, occupational hazards and socio-economic conditions. Tobacco smoke plays a pivotal role in disease development. The complex composition of tobacco smoke contains thousands of harmful substances that damage the airways and lung tissue. Comorbid conditions significantly impact the course of COPD. Considering all disease aspects is essential for a comprehensive treatment approach. Interdisciplinary collaboration among specialists from various fields is an essential prerequisite for successful disease management. The review examines contemporary aspects of multifactorial aspects and multimorbidity in COPD.
About the Authors
А. v Pashkevich
Chita State Medical Academy
Russian Federation
Russian Federation
Candidate of Medical Sciences, Assistant of the Department of Hospital Therapy and Endocrinology
39а Gorky St., Chita, Russia, 672000
Е. А. Belyakova
State Autonomous Health Institution «Transbaikal Regional Clinical Hospital»
Russian Federation
Russian Federation
pulmonologist
7 Kokhansky St., Chita, Russia, 672000
References
1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2023 https://goldcopd.org
2. Adeloye D., Song P., Zhu Y., et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022 Jun.10 (5).447-58. doi: 10.1016/S2213-2600(21)00511-7.
3. Atto B., Eapen MS., Sharma P., et al. New therapeutic targets for the prevention of infectious acute exacerbations of COPD: role of epithelial adhesion molecules and inflammatory pathways. Clin Sci (Lond). 2021 Jul.133(14).1663-703. doi: 10.1042/CS20181009.
4. Christenson SA., Smith BM., Bafadhel M., et al. Chronic obstructive pulmonary disease. Lancet. 2022 May.399(10342).2227-42. doi: 10.1016/S0140-6736(22)00470-6.
5. Lugg ST., Scott A., Parekh D., et al. Cigarette smoke exposure and alveolar macrophages: mechanisms for lung disease. Thorax. 2022 Jan.77(1). 94-101. doi: 10.1136/thoraxjnl-2020-216296.
6. Nicolaou L., Checkley W. Differences between cigarette smoking and biomass smoke exposure: an in silico comparative assessment of particulate deposition in the lungs. Environ Res. 2021 Jun.197.111116. doi: 10.1016/j.envres.2021.111116.
7. Wiegman CH., Li F., Ryffel B., et al. Oxidative stress in ozone-induced chronic lung inflammation and emphysema: a facet of chronic obstructive pulmonary disease. Front Immunol. 2020.11.1957. doi: 10.3389/fimmu.2020.01957.
8. Papke RL. The many enigmas of nicotine. Adv Pharmacol. 2024.99.327-54. doi: 10.1016/bs.apha.2023.08.001.
9. Agustí A., Hogg JC. Update on the pathogenesis of chronic obstructive pulmonary disease. N Engl J Med. 2019 Sep.381(13).1248-56. doi: 10.1056/NEJMra1900475.
10. O’Beirne SL., Kikkers SA., Oromendia C., et al. Alveolar macrophage immunometabolism and lung function impairment in smoking and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020 Mar.201(6).735-9. doi: 10.1164/rccm.201908-1683LE.
11. Shrine N., Guyatt AL., Erzurumluoglu AM., et al. New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. Nat Genet. 2019 Mar.51(3).481-93. doi: 10.1038/s41588-018-0321-7.
12. André S., Conde B., Fragoso E., et al. COPD and Cardiovascular Disease. Pulmonology. 2019 Mar.25(3).168-176. doi: 10.1016/j.pulmoe.2018.09.006.
13. Bhattarai P., Lu W., Gaikwad AV., et al. Arterial remodelling in smokers and in patients with small airway disease and COPD: implications for lung physiology and early origins of pulmonary hypertension. ERJ Open Res. 2022.8(4). doi: 0.1183/23120541.00254-2022.
14. Bhattarai P., Lu W., Hardikar A., et al. Endothelial to mesenchymal transition is an active process in smokers and patients with early COPD contributing to pulmonary arterial pathology. ERJ Open Res. 2024.10(1). doi: 10.1183/23120541.00767-2023.
15. Fiorentino G., Esquinas AM., Annunziata A. Exercise and Chronic Obstructive Pulmonary Disease (COPD). Adv Exp Med Biol. 2020.1228.355-368. doi: 10.1007/978-981-15-1792-1_24.
16. Li Y., Gao H., Zhao L., et al. Osteoporosis in COPD patients: risk factors and pulmonary rehabilitation. Clin Respir J. 2022.16(7).487-496. doi: 10.1111/crj.13514.
17. Pompe E., Bartstra J., Verhaar HJ., et al. Bone density loss on computed tomography at 3-year follow-up in current compared to former male smokers. Eur J Radiol. 2017.89.177-181. doi: 10.1016/j.ejrad.2017.02.011.
18. García-Sanz MT., González-Barcala FJ. COPD is more than just lung function: Let’s not forget depression. Arch Bronconeumol. 2021.57(8).519-520. doi: 10.1016/j.arbr.2021.05.023.
19. Benson VS, Müllerová H, Vestbo J, et al. Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. Respir Med. 2015.109(9).1147-1154. doi: 10.1016/j.rmed.2015.06.009.
20. Lu W., Eapen MS., Hardikar A., et al. Epithelial-mesenchymal transition changes in nonsmall cell lung cancer patients with early COPD. ERJ Open Res. 2023.9(6). doi: 10.1183/23120541.00581-2023.
21. Karacosta LG., Pancirer D., Preiss JS., et al. Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry. Sci Rep. 2023 Jan.13(1).21781. doi: 10.1038/s41598-023-46458-5.
Review
For citations:
Pashkevich А.v., Belyakova Е.А. CURRENT PERSPECTIVE ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE: FROM RISK FACTORS TO MULTIMORBIDITY. Transbaikalian Medical Bulletin. 2026;(2):153-161. (In Russ.) https://doi.org/10.52485/19986173_2026_2_153
Views:
33
JATS XML
Email this article 